aica ribonucleotide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

aica ribonucleotide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Liang, HT; Liu, W; Tang, L; You, Y; Zhu, XJ; Zhu, XY; Zou, P	1
Altman, JK; Donato, NJ; Glaser, H; Platanias, LC; Vakana, E	1

Other Studies

2 other study(ies) available for aica ribonucleotide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity. Current medical science, 2020, Volume: 40, Issue:5 Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides	2020
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood, 2011, Dec-08, Volume: 118, Issue:24 Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Molecular Targeted Therapy; Mutant Proteins; Prodrugs; Protein Kinases; Recombinant Proteins; Ribonucleotides	2011

Article

Year

AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity.

Current medical science, 2020, Volume: 40, Issue:5

Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides

2020

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.

Blood, 2011, Dec-08, Volume: 118, Issue:24

Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Molecular Targeted Therapy; Mutant Proteins; Prodrugs; Protein Kinases; Recombinant Proteins; Ribonucleotides

2011